The ahpC c-54t compensatory mutation is not always a valid surrogate for isoniazid resistance in Mycobacterium tuberculosis.
Szél, Viktória; Phelan, Jody E
; Georghiou, Sophia B; Dolinger, David L; Clark, Taane G; Niemann, Stefan; Lőrinczi, Lilla K; and Köser, Claudio U
(2025)
The ahpC c-54t compensatory mutation is not always a valid surrogate for isoniazid resistance in Mycobacterium tuberculosis.
Antimicrobial agents and chemotherapy, 69 (6).
e0026525-.
ISSN 0066-4804
DOI: 10.1128/aac.00265-25
; Georghiou, Sophia B; Dolinger, David L; Clark, Taane G; Niemann, Stefan; Lőrinczi, Lilla K; and Köser, Claudio U
(2025)
The ahpC c-54t compensatory mutation is not always a valid surrogate for isoniazid resistance in Mycobacterium tuberculosis.
Antimicrobial agents and chemotherapy, 69 (6).
e0026525-.
ISSN 0066-4804
DOI: 10.1128/aac.00265-25
Thirteen commercial genotypic antimicrobial susceptibility assays interrogate mutations upstream of ahpC to infer isoniazid resistance for Mycobacterium tuberculosis. We demonstrate that relying on one of these compensatory mutations (i.e., ahpC c-54t)-rather than causative resistance mutations in katG that ahpC compensates for-can result in systematic false-resistant results for isoniazid with the Cepheid Xpert MTB/XDR and suboptimal treatment. The WHO mutation catalog should be refined to address this scenario.
-
picture_as_pdf - Szél-etal-2025-The-ahpc-c-54t-compensatory-mutation.pdf
-
subject - Published Version
-
- Available under Creative Commons: Attribution 4.0
Downloads